Literature DB >> 19265129

The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis.

Muhammad Zaeem Noman1, Stéphanie Buart, Jos Van Pelt, Catherine Richon, Meriem Hasmim, Nathalie Leleu, Wictoria Maria Suchorska, Abdelali Jalil, Yann Lecluse, Faten El Hage, Massimo Giuliani, Christophe Pichon, Bruno Azzarone, Nathalie Mazure, Pedro Romero, Fathia Mami-Chouaib, Salem Chouaib.   

Abstract

Hypoxia is an essential component of tumor microenvironment. In this study, we investigated the influence of hypoxia (1% PO(2)) on CTL-mediated tumor cell lysis. We demonstrate that exposure of target tumor cells to hypoxia has an inhibitory effect on the CTL clone (Heu171)-induced autologous target cell lysis. Such inhibition correlates with hypoxia-inducible factor-1alpha (HIF-1alpha) induction but is not associated with an alteration of CTL reactivity as revealed by granzyme B polarization or morphological change. Western blot analysis indicates that although hypoxia had no effect on p53 accumulation, it induced the phosphorylation of STAT3 in tumor cells by a mechanism at least in part involving vascular endothelial growth factor secretion. We additionally show that a simultaneous nuclear translocation of HIF-1alpha and phospho-STAT3 was observed. Interestingly, gene silencing of STAT3 by small interfering RNA resulted in HIF-1alpha inhibition and a significant restoration of target cell susceptibility to CTL-induced killing under hypoxic conditions by a mechanism involving at least in part down-regulation of AKT phosphorylation. Moreover, knockdown of HIF-1alpha resulted in the restoration of target cell lysis under hypoxic conditions. This was further supported by DNA microarray analysis where STAT3 inhibition resulted in a partly reversal of the hypoxia-induced gene expression profile. The present study demonstrates that the concomitant hypoxic induction of phospho-STAT3 and HIF-1alpha are functionally linked to the alteration of non-small cell lung carcinoma target susceptibility to CTL-mediated killing. Considering the eminent functions of STAT3 and HIF-1alpha in the tumor microenvironment, their targeting may represent novel strategies for immunotherapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19265129     DOI: 10.4049/jimmunol.0800854

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  68 in total

Review 1.  HIF transcription factors, inflammation, and immunity.

Authors:  Asis Palazon; Ananda W Goldrath; Victor Nizet; Randall S Johnson
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

Review 2.  Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia.

Authors:  Muhammad Zaeem Noman; Meriem Hasmim; Yosra Messai; Stéphane Terry; Claudine Kieda; Bassam Janji; Salem Chouaib
Journal:  Am J Physiol Cell Physiol       Date:  2015-08-26       Impact factor: 4.249

3.  Hypoxia-inducible factor-1alpha enhances haptoglobin gene expression by improving binding of STAT3 to the promoter.

Authors:  Mi-Kyung Oh; Hyo-Jung Park; Nam-Hoon Kim; Seon-Joo Park; In-Yang Park; In-Sook Kim
Journal:  J Biol Chem       Date:  2011-01-11       Impact factor: 5.157

Review 4.  Modulation of Inflammatory Response to Implanted Biomaterials Using Natural Compounds.

Authors:  Maria Yanez; James Blanchette; Ehsan Jabbarzadeh
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

5.  Gain of HIF-1α under normoxia in cancer mediates immune adaptation through the AKT/ERK and VEGFA axes.

Authors:  Young-Ho Lee; Hyun Cheol Bae; Kyung Hee Noh; Kwon-Ho Song; Sang-kyu Ye; Chih-Ping Mao; Kyung-Mi Lee; T-C Wu; Tae Woo Kim
Journal:  Clin Cancer Res       Date:  2015-01-14       Impact factor: 12.531

Review 6.  HIF-1 at the crossroads of hypoxia, inflammation, and cancer.

Authors:  Kuppusamy Balamurugan
Journal:  Int J Cancer       Date:  2015-04-07       Impact factor: 7.396

7.  Interleukin-23 engineering improves CAR T cell function in solid tumors.

Authors:  Xingcong Ma; Yang Xu; Peishun Shou; Christof Smith; Yuhui Chen; Hongwei Du; Chuang Sun; Nancy Porterfield Kren; Daniel Michaud; Sarah Ahn; Benjamin Vincent; Barbara Savoldo; Yuliya Pylayeva-Gupta; Shuqun Zhang; Gianpietro Dotti
Journal:  Nat Biotechnol       Date:  2020-02-03       Impact factor: 54.908

8.  Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.

Authors:  Kohei Shigeta; Meenal Datta; Tai Hato; Shuji Kitahara; Ivy X Chen; Aya Matsui; Hiroto Kikuchi; Emilie Mamessier; Shuichi Aoki; Rakesh R Ramjiawan; Hiroki Ochiai; Nabeel Bardeesy; Peigen Huang; Mark Cobbold; Andrew X Zhu; Rakesh K Jain; Dan G Duda
Journal:  Hepatology       Date:  2019-10-14       Impact factor: 17.425

Review 9.  Enhanceosomes as integrators of hypoxia inducible factor (HIF) and other transcription factors in the hypoxic transcriptional response.

Authors:  Matthew R Pawlus; Cheng-Jun Hu
Journal:  Cell Signal       Date:  2013-05-21       Impact factor: 4.315

Review 10.  Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer.

Authors:  Michail Sitkovsky; Akio Ohta
Journal:  J Mol Med (Berl)       Date:  2013-01-20       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.